Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease
暂无分享,去创建一个
J. Silverberg | R. Higgs | S. C. Colvin | E. Simpson | S. Forman | Yushi Liu | G. Rodgers | E. Guttman‐Yassky | J. Janes | S. Sissons | J. Sims | Ching-yun Chang | S. Engle | E. Guttman-Yassky
[1] J. Krueger,et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. , 2020, Journal of the American Academy of Dermatology.
[2] Hyun Je Kim,et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. , 2020, The Journal of allergy and clinical immunology.
[3] J. Silverberg,et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials , 2020, The British journal of dermatology.
[4] A. Paller,et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. , 2019, Journal of the American Academy of Dermatology.
[5] James T. Elder,et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. , 2019, The Journal of investigative dermatology.
[6] P. Brunner,et al. Racial differences in atopic dermatitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] Ning Zhang,et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[8] T. Nomura,et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis , 2018, Nature Immunology.
[9] S. Kežić,et al. Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell‐related immunity and angiogenesis , 2018, The British journal of dermatology.
[10] H. Wen,et al. Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features. , 2018, The Journal of allergy and clinical immunology.
[11] J. Silverberg,et al. Epidemiology of adult atopic dermatitis. , 2018, Clinics in dermatology.
[12] T. Honda,et al. Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. , 2018, The Journal of allergy and clinical immunology.
[13] M. Schön,et al. The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis , 2018, Front. Immunol..
[14] Ning Zhang,et al. Early‐onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22‐centered inflammation and lipid alterations , 2018, The Journal of allergy and clinical immunology.
[15] M. Seibold,et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2–high atopic dermatitis disease endotype , 2018, The Journal of allergy and clinical immunology.
[16] A. Alexis,et al. Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment , 2018, Experimental dermatology.
[17] T. Mustelin,et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. , 2018, The Journal of allergy and clinical immunology.
[18] J. Silverberg,et al. Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: A phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study , 2018, Journal of the American Academy of Dermatology.
[19] M. D. de Bruin‐Weller,et al. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. , 2017, The Journal of allergy and clinical immunology.
[20] David M. Evans,et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts , 2017, Pediatrics.
[21] T. Mustelin,et al. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis , 2017, The Journal of allergy and clinical immunology.
[22] A. Dattola,et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins , 2017, Scientific Reports.
[23] M. Suárez-Fariñas,et al. Identification of unique proteomic signatures in allergic and non‐allergic skin disease , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[24] Hiromi Mizutani,et al. Serum IL-21 levels are elevated in atopic dermatitis patients with acute skin lesions. , 2017, Allergology international : official journal of the Japanese Society of Allergology.
[25] J. Krueger,et al. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. , 2017, The Journal of allergy and clinical immunology.
[26] Donald Y M Leung,et al. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. , 2017, The Journal of allergy and clinical immunology.
[27] Thomas Bieber,et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? , 2017, The Journal of allergy and clinical immunology.
[28] M. Suárez-Fariñas,et al. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. , 2017, The Journal of investigative dermatology.
[29] J. Silverberg,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.
[30] C. Akdis,et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.
[31] M. Suárez-Fariñas,et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.
[32] C. Flohr,et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis , 2015, Current opinion in allergy and clinical immunology.
[33] A. Paller,et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. , 2015, The Journal of allergy and clinical immunology.
[34] E. Guttman‐Yassky,et al. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics , 2015, Journal of clinical medicine.
[35] M. D. de Bruin‐Weller,et al. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. , 2014, Journal of the American Academy of Dermatology.
[36] M. Suárez-Fariñas,et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.
[37] Y. Tokura. Extrinsic and intrinsic types of atopic dermatitis. , 2010, Journal of dermatological science.
[38] T. Mosmann,et al. T helper cytokine patterns: defined subsets, random expression, and external modulation , 2009, Immunologic research.
[39] S. Stevens,et al. Interferon-gamma therapy reduces blood leukocyte levels in patients with atopic dermatitis: correlation with clinical improvement. , 1999, Clinical immunology.
[40] J. Krueger,et al. Increased cardiovascular and atherosclerosis markers in blood of older atopic dermatitis patients. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[41] Y. Tokura,et al. Sensitive skin is highly frequent in extrinsic atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier impairment. , 2018, Journal of dermatological science.
[42] J. Silverberg,et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. , 2017, The Journal of investigative dermatology.
[43] M. Mack,et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease , 2003, Nature Medicine.
[44] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .